Biodexa Pharmaceuticals Plc

NasdaqCM:BDRX Voorraadrapport

Marktkapitalisatie: US$3.4m

Biodexa Pharmaceuticals Toekomstige groei

Future criteriumcontroles 0/6

Biodexa Pharmaceuticals's revenue is forecast to decline at 70.6% per annum.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Biotechs winstgroei27.1%
Inkomstengroei-70.6%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt04 Jun 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Midatech Pharma regains compliance with Nasdaq's minimum bid price requirement

Oct 18

Midatech Pharma reports 1H results

Sep 14

Midatech surges on the promise of drug delivery system

Jun 17

Winst- en omzetgroeiprognoses

NasdaqCM:BDRX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (GBP Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20260N/AN/AN/A1
12/31/20250N/AN/AN/A1
12/31/20240N/AN/AN/A1
6/30/20240-7-9-8N/A
3/31/20240-7-8-7N/A
12/31/20230-7-7-7N/A
9/30/20230-8-7-7N/A
6/30/20231-8-7-7N/A
3/31/20231-8-7-7N/A
12/31/20221-8-7-7N/A
9/30/20221-7-7-7N/A
6/30/20221-5-7-6N/A
3/31/20221-5-6-6N/A
12/31/20211-5-6-6N/A
9/30/20211-7-6-6N/A
6/30/20211-8-6-5N/A
3/31/20210-15-8-7N/A
12/31/20200-22-10-9N/A
6/30/20200-22-9-9N/A
3/31/20201-16-8-8N/A
12/31/20191-9-7-6N/A
6/30/20192-9-10-10N/A
3/31/20192-10-12-12N/A
12/31/20182-10-14-13N/A
6/30/20181-11-11-11N/A
3/31/20181-11N/A-12N/A
12/31/20171-12N/A-13N/A
9/30/2017-3-1N/A-14N/A
6/30/20174-18N/A-15N/A
3/31/20176-19N/A-14N/A
12/31/20161-6N/A-13N/A
9/30/20165-17N/A-14N/A
6/30/20164-13N/A-15N/A
3/31/20163-12N/A-14N/A
12/31/20151-10N/A-12N/A
9/30/20151-10N/A-11N/A
6/30/20150-11N/A-9N/A
3/31/20150-10N/A-7N/A
12/31/20140-9N/A-5N/A
9/30/20140-7N/A-5N/A
6/30/20140-5N/A-5N/A
3/31/20140-4N/A-5N/A
12/31/20130-4N/A-4N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if BDRX's forecast earnings growth is above the savings rate (2.5%).

Winst versus markt: Insufficient data to determine if BDRX's earnings are forecast to grow faster than the US market

Hoge groeiwinsten: Insufficient data to determine if BDRX's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: BDRX's revenue is expected to decline over the next 3 years (-70.6% per year).

Hoge groei-inkomsten: BDRX's revenue is forecast to decline over the next 3 years (-70.6% per year).


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if BDRX's Return on Equity is forecast to be high in 3 years time


Ontdek groeibedrijven